PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings • Assumptions PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Biosimilars: Overview • Comparative analysis of generic small molecules and biosimilars • Biosimilars market opportunities • Challenges for new entrants • Bio-betters PART 05: Pipeline portfolio PART 06: Market landscape • Market overview • Five forces analysis PART 07: Market segmentation by application • Global chronic and autoimmune diseases mAb biosimilars market • Global oncology mAb biosimilars market PART 08: Geographical segmentation • Global mAb biosimilars market by geographical segmentation 2015-2020 • mAb biosimilars market in Europe • mAb biosimilars market in Asia • mAb biosimilars market in rest of the world PART 09: Market drivers • Rise in number of patent expiries • Need for cost-effective treatment • Reimbursement benefits for biosimilars • Favorable government regulations PART 10: Impact of drivers PART 11: Market challenges • Physicians' reluctance to prescribe biosimilars • Multiple manufacturing complexities • Risks related to drug failure • Limited availability of biosimilar products • Difficulties in patient recruitment for clinical trials PART 12: Impact of drivers and challenges PART 13: Market trends • Emergence of biosimilars • Outsourcing of manufacturing activities • Need for high investment in R&D • High growth in the emerging markets • Rising number of strategic collaborations PART 14: Vendor landscape • Competitive scenario PART 15: Key vendor analysis • Biocon • Celltrion • Dr. Reddy's Laboratories • Hospira • Other prominent vendors PART 16: Appendix • List of abbreviations PART 17: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Global mAb biosimilars market: Snapshot Exhibit 03: Global mAb biosimilars market: Growth analysis Exhibit 04: Global mAb biosimilars market: Key buying criteria 2015 Exhibit 05: Global mAb biosimilars market: Timeline 2014-2020 Exhibit 06: Global mAb biosimilars market: Impact of key customer segments 2015 Exhibit 07: Definition of biosimilars by agencies Exhibit 08: Comparison between generic small molecules and biosimilars Exhibit 09: Impact of biosimilars cost savings on different sectors Exhibit 10: Factors affecting success of biosimilars Exhibit 11: Biosimilars industry: Point-of-view Exhibit 12: Factors influencing uptake of biosimilars Exhibit 13: Global mAb biosimilars market: Strategic factors for new market entrants Exhibit 14: Challenges for new entrants Exhibit 15: Bio-betters and its impact on market Exhibit 16: Global mAb biosimilars market: Pipeline snapshot 2015 Exhibit 17: Pipeline portfolio: Global mAb biosimilars market 2015 Exhibit 18: Patent expiry in key mAb biosimilars markets 2000-2020 Exhibit 19: Global mAb biosimilars market: Developed and emerging markets 2015 Exhibit 20: Global mAb biosimilars market 2015-2020 ($ millions) Exhibit 21: Biosimilars: Savings potential in five European countries and US ($ billions) 2016-2020 Exhibit 22: Global spending on mAb biosimilars 2010-2020 ($ billions) Exhibit 23: Global mAb biosimilars market: Key metrics analysis snapshot Exhibit 24: Current and future trends in global mAb biosimilars market Exhibit 25: Factors influencing the global mAb biosimilars market 2015 Exhibit 26: Five forces analysis Exhibit 27: Global mAb biosimilars market: Segmentation by application (2015-2020) Exhibit 28: Applications of mAb biosimilars and its impact on growth of market Exhibit 29: Global mAb biosimilars market segmentation: Growth cycle analysis Exhibit 30: Population aged 60 years and over (millions) Exhibit 31: Global chronic and autoimmune diseases mAb biosimilars market 2015-2020 ($ millions) Exhibit 32: Opportunity analysis of chronic and autoimmune diseases mAb biosimilars market by application Exhibit 33: Global incidence of cancer 2015-2020 (millions) Exhibit 34: Global oncology mAb biosimilars market 2015-2020 ($ millions) Exhibit 35: Opportunity analysis of global oncology mAb biosimilars market by type of application Exhibit 36: Global mAb biosimilars market segmentation by application 2015 Exhibit 37: Global mAb biosimilars market by geography: Outlook 2015-2020 Exhibit 38: Global mAb biosimilars market by geography 2015 Exhibit 39: Market penetration of originators and biosimilars by region/country Exhibit 40: Global mAb biosimilars market landscape: Country analysis Exhibit 41: mAb biosimilars market in Europe: Opportunity analysis Exhibit 42: mAb biosimilars market in Europe 2015-2020 ($ millions) Exhibit 43: PEST analysis: mAb biosimilars market in Europe 2015 Exhibit 44: mAb biosimilars market in Asia: Opportunity analysis Exhibit 45: mAb biosimilars market in Asia 2015-2020 ($ millions) Exhibit 46: PEST analysis: mAb biosimilars market in Asia 2015 Exhibit 47: mAb biosimilars market in rest of the world: Opportunity analysis Exhibit 48: mAb biosimilars market in rest of the world 2015-2020 ($ millions) Exhibit 49: Benefits of mAb biosimilars to US healthcare system Exhibit 50: PEST analysis: mAb biosimilars market in rest of the world 2015 Exhibit 51: Impact of drivers and challenges on global mAb biosimilars market Exhibit 52: Patent analysis of mAb in the US Exhibit 53: Patent analysis of biologicals in Europe Exhibit 54: Impact of drivers Exhibit 55: Physicians' reluctance to prescribe biosimilars: Key reasons Exhibit 56: Impact of drivers and challenges Exhibit 57: Global mAb biosimilars market: Impact assessment of key trends Exhibit 58: Competitive assessment of vendors Exhibit 59: Key vendors: Geographical presence 2015 Exhibit 60: Major vendors in global mAb biosimilars market: Mergers, acquisitions, and partnerships Exhibit 61: Biocon profile Exhibit 62: Biocon: Metrics analysis Exhibit 63: Biocon growth strategy matrix Exhibit 64: Biocon: Opportunity assessment Exhibit 65: Celltrion profile Exhibit 66: Celltrion: Metrics analysis Exhibit 67: Celltrion growth strategy matrix Exhibit 68: Celltrion: opportunity assessment Exhibit 69: Dr. Reddy's Laboratories profile Exhibit 70: Dr. Reddy's Laboratories: Metrics analysis Exhibit 71: Dr. Reddy's Laboratories growth strategy matrix Exhibit 72: Dr. Reddy's Laboratories Opportunity assessment Exhibit 73: Hospira profile Exhibit 74: Hospira: Metrics analysis Exhibit 75: Hospira growth strategy matrix Exhibit 76: Hospira opportunity growth assessment

Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan, Alvartis Pharma, Amega Biotech, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Bharat Serums, Bio Sidus, Biogen, Bionovis, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Boston Oncology, Cipla, Coherus Biosciences, Daiichi Sankyo, Emcure Pharmaceuticals, Gedeon Richter, GeneScience Pharmaceuticals, GSK, Hetero Drugs, iBio, Intas Pharmaceuticals, JCR Pharmaceuticals, LG Lifesciences, Lonza, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Mylan, Natco Pharma, Novartis, Pfenex, Pfizer, Ranbaxy Laboratories, Roche Holding, Samsung Biologics, Sanofi, and Synthon.